The purpose of this study is to find out about the safety and efficacy of T4032, which is a preservative-free formulation of bimatoprost (0.01%) for the treatment of glaucoma or ocular (eye) hypertension. There will be 5 to 6 study visits and participation will last up to 12 weeks (120 days), including the screening and wash-out periods. Study visits during the treatment period (Day 1 to Day 85) will last approximately 8-10 hours. Participants will be compensated maximum $500 for completion of all study visits.

You may be eligible for this study if you meet the following criteria:

• Conditions: ocular hypertension
• Age: 18 years - 99 years
• Gender: All